BLRX — BioLine RX Balance Sheet
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall CapMomentum Trap
- $89.48m
- $42.60m
- 18
- 30
- 77
- 36
Annual balance sheet for BioLine RX, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 49.5 | 30.2 | 27.5 | 22.6 | 57.1 |
| Net Total Receivables | 0.586 | 1.34 | 0.613 | 0.141 | 0.142 |
| Prepaid Expenses | |||||
| Total Current Assets | 50.4 | 32 | 28.2 | 22.9 | 57.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.5 | 2.23 | 3.47 | 2.7 | 2.28 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 61 | 56.2 | 53.6 | 47.3 | 81.4 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.72 | 6.75 | 12 | 10.6 | 9.72 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.08 | 14.9 | 20.2 | 25.3 | 13.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 52.9 | 41.3 | 33.4 | 22 | 68.1 |
| Total Liabilities & Shareholders' Equity | 61 | 56.2 | 53.6 | 47.3 | 81.4 |
| Total Common Shares Outstanding |